The FDA has set a meeting with GlaxoSmithKline on July 30 to discuss its Avandia diabetes drug, cited by some studies as increasing the risk of heart attacks. The session is a fact-gathering meeting aimed at settling issues involving the drug to control blood-sugar levels in diabetics.

Related Summaries